Comparing 3D Imaging and CT Scans to Assess Treatment Response in Patients with Borderline or Locally Advanced Pancreatic Adenocarcinoma

What this Trial Is About

Researchers are investigating the accuracy of a new 3D imaging technology called the 3D-PANC MSP model compared to traditional computed tomography CT scans in evaluating patients with borderline or locally advanced pancreatic adenocarcinoma PAC who have undergone neoadjuvant chemotherapy. The study aims to determine if the 3D technology better identifies which patients might benefit from surgical removal of their cancer by comparing imaging results to actual surgery and tissue analysis findings. All patients will receive both the standard CT scan and the 3D-MSP imaging before surgery. The 3D models will be centrally created and analyzed by specialists who do not know the surgical outcomes. Each patient will serve as their own control as the study compares the two imaging methods accuracy in detecting vascular involvement and response to chemotherapy. Participants will be monitored through preoperative imaging and surgical exploration with tissue analysis as the reference standard. The study will track measures such as sensitivity, specificity, and predictive values of both imaging techniques. Additional analysis will assess the usefulness of 3D imaging for surgical planning and patient communication. The study duration includes the period through surgery and postoperative evaluation, averaging about two months for outcome measurement.

Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?